Lung cancer is the most commonly diagnosed cancer; of which non-small cell lung cancer (NSCLC) accounting for approximately 80% of newly diagnosed lung cancer. The prognosis of lung tumors depends on early and accurate staging and the histopathological type of the tumor.^[1]

Although CT scanning has long been the go-to imaging modality to stage lung cancer, it is hindered by many limitations and pitfalls. It may be unable to distinguish a tumor from atelectasis, does not reflect tumoral metabolic activity and gives no idea about the pathology of the tumor.^[2] This can have negative outcome on patient’s treatment plans and prognosis.^[3]

Fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG PET/CT) imaging depends on glucose metabolism of tumor cells and has been applied primarily as a staging and restaging tool that can guide subsequent patient care. ^[1] It is been suggested that NSCLC with different pathological types and sizes produce different max.SUV values on PET/CT.^[4]

Thus, a better understanding of biological mechanisms involved in lung tumor cells provided by combined PET/CT can be helpful and lead to a better selection of treatment modalities for patients and better prognosis.^[5]